Solid forms of fasoracetam

Patent metadata

Field	Value
Publication number	US-2023203001-A1
Application number	US-202318170306-A
Country	US
Kind code	A1
Filing date	Feb 16, 2023
Priority date	Jan 18, 2018
Publication date	Jun 29, 2023
Grant date	—

Abstract

The disclosure is directed to cocrystals of fasoracetam, including R-fasoracetam, and various coformers. Crystalline materials comprising fasoracetam, including R-fasoracetam, are also provided. The disclosure further includes pharmaceutical compositions and methods of treatment of the cocrystals and crystalline materials of the disclosure.

First claim

1 .- 3 . (canceled)

4 . A crystalline compound or cocrystal comprising fasoracetam and a coformer, wherein the coformer is an aromatic compound, which is optionally substituted with one, two, three, or four substituents selected from the group consisting of OH, NH 2 , alkyl, —NO 2 , and a carbonyl-containing moiety.

5 .- 12 . (canceled)

13 . The crystalline compound or cocrystal of claim 4 , wherein the organic acid moiety is —COOH.

14 .- 16 . (canceled)

17 . The crystalline compound or cocrystal of claim 4 , wherein the aromatic compound has two, three, or four substituents, each of which are independently selected from the group consisting of —OH, —NH 2 , alkyl, organic acid, ester, and —NO 2 .

18 .- 57 . (canceled)

58 . The crystalline compound or cocrystal of claim 4 , wherein the aromatic compound is polycyclic, optionally wherein the aromatic compound comprises two six-membered rings or a six-membered ring and a five-membered ring.

59 .- 61 . (canceled)

62 . The crystalline compound or cocrystal of claim 4 , wherein the aromatic compound comprises all carbon ring atoms.

63 . The crystalline compound or cocrystal of claim 4 , wherein at least one ring atom of the aromatic compound is not carbon.

64 . The crystalline compound or cocrystal of claim 4 , wherein at least one ring atom of the aromatic compound is nitrogen.

65 . The crystalline compound or cocrystal of claim 58 , the polycyclic aromatic compound is optionally substituted with at least one substituent selected from the group consisting of OH, NH 2 , alkyl, —NO 2 , and a carbonyl-containing moiety.

66 .- 332 . (canceled)

333 . The crystalline compound or cocrystal of claim 4 , wherein the aromatic compound contains an aromatic ring fused to at least one non-aromatic cyclic moiety.

334 .- 336 . (canceled)

337 . A pharmaceutical composition comprising a crystalline compound or cocrystal of claim 4 and one or more pharmaceutically acceptable excipients.

338 . A method of treating attention-deficit hyperactive disorder (ADHD) in human subject in need thereof, the method comprising administering to the subject the crystalline compound or cocrystal of claim 4 .

339 . The method of claim 338 , wherein the subject has at least one copy number variation (CNV) in a metabotropic glutamate receptor (mGluR) network gene.

340 .- 371 . (canceled)

Assignees

• Childrens Hospital Philadelphia

Inventors

• Leyssens Tom
• Couch Richard Alan
• Guillot Michael Paul Rene
• Harmsen Bram
• Bailey Thomas R
• Appelmans Martin

Classifications

• C07C275/02

  Salts; Complexes; Addition compounds · CPC title

• C07C65/11

  with carboxyl groups on a condensed ring system containing two rings · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07C39/10

  Polyhydroxy benzenes; Alkylated derivatives thereof (C07C39/08 takes precedence) · CPC title

• C07C69/88

  with esterified carboxyl groups · CPC title